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We describe three cases of acute gastroenteritis in healthy infants after vaccination with 
RotaTeq vaccine, shedding a G1P[8] human-bovine double reassortant rotavirus in stools. Such a 
double reassortant virus appears stable in vitro and may explain diarrheal symptpms in a small 
percentage of RotaTeq recipients, and might also be transmitted to contacts in the 
environment. 
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Suomenkielinen tiivistelmä: 
 
Rotavirukset ovat maailmanlaajuisesti yleisin pienten lasten vakavien ripulitautien 
aiheuttaja. Ennen rotavirusrokotuksia lasten rotavirusinfektiot aiheuttivat 
vuosittain kymmeniätuhansia sairaala- ja poliklinikkakäyntejä pienillä lapsilla.  
RotaTeq® rokote lisättiin Suomen kansalliseen rokotusohjelmaan syyskuussa 
2009, kun se oli massiivisten tutkimusten jälkeen todettu turvalliseksi ja 
tehokkaaksi rokotteeksi rotavirus tautia vastaan. RotaTeq® on elävä, heikennetty 
rokote, joka sisältää viittä ihmisen ja naudan yhdistelmävirusta. 
Yhdistelmäviruksissa toinen ulommista pintaproteiineista, VP7 tai VP4, on 
ihmisperäinen ja toinen nautaperäinen. Suomessa immunisointi tapahtuu 2, 3 ja 
5 kuukauden ikäisenä. 
 
Tutkimuksen tarkoituksena oli selvittää Tampereen yliopistollisessa sairaalassa 
(TAYS) syyskuun 2009 ja elokuun 2011 välillä hoidettujen oksennus- ja/tai 
ripulitautia sairastavien lasten pääasiallisia taudinaiheuttajia. Tutkimukseen 
osallistuneilta lapsilta kerättiin ulostenäyte, josta tutkittiin rotaviruksen lisäksi 
norovirus, adenovirus, coronavirus sekä bocavirus PCR- menetelmillä. Rotavirus 
positiivisista näytteistä selvitettiin lisäksi viruksen uloimman kerroksen kahden 
pintaproteiinin, VP7 ja VP4 genomi viruksen tyypitystä varten, sekä 
keskikerroksen proteiinin VP6 sekvenssi mahdollisen rokoteviruksen 
tunnistamiseksi. 
 
Tutkimuksessa löydettiin 3 lasta, joilla oksennus-ja/tai ripulitaudin aiheuttaja oli 
rokotteesta peräisin oleva uusi yhdistelmävirus. Uudessa rokoteperäisessä 
viruksessa kaksi RotaTeq® rokotteen virusta ovat yhdistyneet siten, että 
muodostuneen uuden yhdistelmäviruksen uloimman kerroksen kumpikin 
proteiini, VP7 ja VP4, ovat ihmisperäisiä. Merkittävänä tutkimustuloksena selvisi, 
että uusi rokoteperäinen yhdistelmävirus on infektiivinen ja stabiili.  Se voi 
aiheuttaa oksennus-ja/tai ripulitaudin oireita rokotetuilla lapsilla, jotka voivat 
erittää virusta edelleen ympäristöönsä.  
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INTRODUCTION 
 
RotaTeq® (RV5, Merck&Co. Inc., in Europe SanofiPasteur-MSD) is an oral live-
attenuated human-bovine reassortant vaccine that contains five reassortants on 
bovine G6P[5] rotavirus backbone, four of which express the human VP7 antigen 
G1,G2,G3 or G4, respectively. One reassortant expresses human VP4 P1A[8] 
and retains VP7 type G6 from the bovine rotavirus parent strain WC3.1-3 
RotaTeq® was licenced in 2006 following a large trial called REST (RotaTeq 
Efficacy and Safety Trial), involving 70,000 infants.1 In the US, the incorporation 
of RotaTeq® into routine immunization program has been highly successful in 
preventing hospitalizations and emergency department visits due to wild-type 
rotavirus gastroenteritis.4-6 Rotavirus vaccination was introduced into the Finnish 
National Immunization Program as of September 1, 2009, and RotaTeq® has 
been exclusively used in Finland since then. In Finland, RotaTeq® is given in 
three doses at ages 2, 3 and 5 months. The vaccination coverage is about 96%, 
or approximately 56,000 vaccinated children annually (Source: National Institute 
of Health and Welfare (THL), Finland). 
  
RotaTeq® is generally regarded as a very safe vaccine. However, a small 
increase in diarrhea and vomiting in the first week after the first dose has been 
observed in large materials. 2,3  Recently, diarrhea in children after RotaTeq® 
vaccination was reported from the US7,8 and Australia.(Kirkwood CD, Donato C, 
Ch’ng LS, et al. Identification of RotaTeq® vaccine in paediatric patients with 
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acute gastroenteritis following routine vaccination. In: Vaccines for Enteric 
Diseases, Cannes, France, 2011. Poster presentation) The diarrhea was 
associated with the formation of a new human-bovine double reassortant 
between G1P[5] and G6P[8] strains from the pentavalent vaccine.8 
We describe three cases of acute gastroenteritis after RotaTeq® vaccination in 
healthy infants, all of whom shed such a G1P[8] double reassortant in the 
absence of other viral pathogens. 
 
 
METHODS 
 
A prospective study on the etiology of acute gastroenteritis (AGE) in children 
started on 1 September 2009 in Tampere University Hospital concurrently with 
the introduction of RotaTeq® vaccine and was conducted until 31 August 2011. 
The study was approved by The Ethics Committee of Pirkanmaa Hospital 
District. Patients with AGE less than 16 years of age, who were seen in the 
emergency department (ED) of the hospital or were admitted to a pediatric ward, 
were eligible for the study, subject to obtaining informed consent from the 
parents.  
 
Stool specimens were collected from 316 patients and examined at the Vaccine 
Research Center of the University of Tampere Medical School. The stools were 
collected in the outpatient clinic or, if the patient was hospitalized, in the ward, 
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and studied by reverse transcription-polymerase chain reaction (RT-PCR) 
methods for several gastroenteritis viruses, including rotavirus. Of all enrolled 
subjects 79 (25%) were rotavirus positive and of these 17 had received at least 
one dose of RotaTeq® vaccine. Rotavirus G and P genotypes were determined 
by nucleotide sequencing of the gene segments encoding for the VP7 and VP4 
antigens 9, respectively, and of the gene segment encoding for VP6 to determine 
the presence of vaccine derived virus.  
 
For the VP6 RT-PCR, a method was kindly provided by Max Ciarlet, based on 
the method described by Iturriza-Gómara et al10 , and adapted at Merck, 
Research Laboratories. 
Briefly, the 379 bp amplicons of the VP6 genes were obtained using primers 
Rota VP6-Fs (forward primer): 5′GAYGGNGCDACNACATGGT3′ (nt 747–765) 
and Rota VP6-Rs (reverse primer): 5′GTCCARTTCATNCCTGGYGG3′ (nt 1107–
1126) synthesized in Sigma-Genosys Ltd.. For Y(C,T), R(A,G), D(A,G,T) and 
N(A,G,C,T). The oligonucleotides were designed based on the sequence of the 
Wa (human) VP6 (Access no; K02086) and WC3 (bovine) VP6 (Access no; 
AF411322) genes.  
  
The RT-PCR primers were further used as sequencing primers. Gel purified 
amplicons (QIAquick Gel Extraction Kit, Qiagen) were sequenced using BigDye 
Terminator v1.1 Cycle Sequencing v1.1 Ready Reaction Kit with AmpliTaq DNA 
Polymerase FS (Applied Biosystems) on an ABI Prism 310 Genetic Analyzer. 
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Nucleotide sequences read from the chromatograms were aligned to published 
sequences from GenBank. 
Stool specimens from patients who had received RotaTeq® vaccine were also 
tested for presence of rotavirus antigen by ELISA, using the IDEIA Rotavirus Kit 
(Oxoid Ltd, UK). The rotavirus ELISA positive stool specimen from Patient 3 was 
propagated in MA104 cells as described previously.11 For other gastroenteritis 
viruses, norovirus, sapovirus and bocavirus were tested as described 
previously.12,13 Coronavirus was tested as described by Risku et al. (Human 
bocavirus types 1, 2 and 3 in acute gastroenteritis of childhood. Paper submitted 
to Acta Pediatrica). 
 
CASE REPORTS 
 
Patient 1 
A two-month-old girl had received the first dose of RotaTeq® vaccine in March 
2010, 7 days before the onset of diarrhea. She was taken to the ED on the third 
day of illness after she had had diarrhea for two days (day 1: 15 loose stools, day 
2: 5 loose stools). In the ED, she was pale and sleepy, had blood in her stools, 
and a rectal temperature of 37.8 °C. The extremities were warm, the mouth and 
tongue were moist, but she refused to drink. The estimated dehydration rate was 
1-2%. The patient was rehydrated with an oral rehydration solution and 
discharged, but at home the diarrhea continued for another 5 days. 
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The infant had reached full gestational age but had had cardiac surgery one 
week after birth due to tetralogy of Fallot. She was growing and developing well, 
was breastfed, and, except for the follow-up of the heart surgery, did not have 
any hospitalizations or diseases. 
 
Patient 2 
A three-month-old boy had received the second dose of RotaTeq® vaccine in 
April 2011, one day before the onset of diarrhea. He was taken to the ED on the 
eighth day of illness when his general condition was getting worse. The infant 
had approximately 10 loose stools of greenish or yellowish colour per day. On 
admission he had a rectal temperature of 37.3 °C, the abdomen was tender, and 
there was slight reddish rash on the abdomen. He had instant recoil on skin 
turgor test, and his general condition was good. He had no breastfeeding 
problem and was discharged. 
The infant had had no side effects after the first dose of RotaTeq® vaccine. He 
was born in the 37th week and was growing and developing normally. 
Concomitantly with the second dose of RotaTeq®, he had received Infanrix 
Penta (GSK) vaccine containing the diphtheria, tetanus, pertussis, Haemophilus 
influenzae type b (Hib) and inactivated polio virus (IPV) components. 
 
Patient 3 
A two-month-old girl had received the first dose of RotaTeq® vaccine in August 
2011, five days before she was taken to the ED. Before admission, she had had 
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vomiting for one day, diarrhea with a maximum of 12 loose stools a day and a 
rectal temperature up to 38.1 °C. On admission, she had a moist mouth and 
tongue and instant recoil on skin turgor test, but a sunken fontanel. The infant 
was irritable and due to vomiting had problems with breastfeeding; therefore 
overnight admission was required. She was discharged the next day, still having 
a temperature of 37.8’C but no diarrhea or vomiting. The fecal specimen was 
collected on the second day in hospital. 
The infant was full term, was growing and developing normally, and had no 
previous medications, diseases or hospitalizations. 
 
Other Cases 
The same G1P[8] double reassortant human-bovine rotavirus as in patients 1-3 
was also found from a three-month-old girl who had received her second dose of 
RotaTeq® 16 days before hospital admission because of gastroenteritis. In this 
case norovirus was detected in the same stool specimen, and it was assumed 
that the principal cause of gastroenteritis symptoms was norovirus, which had 
infected all family members earlier the same week.  
 
Additionally, one gastroenteritis patient was found to shed a single reassortant 
vaccine virus G6P[8]. This two-month-old boy had received the first dose of 
RotaTeq® vaccine five days before he was taken to the ED due to forceful 
vomiting. Even though the vomiting had started only one day before, an overnight 
admission was required and the infant was rehydrated with an oral rehydration 
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solution before discharge. In the hospital the child had no fever or diarrhea. Tests 
for other gastroenteritis viruses were negative. 
 
In the same study material, we also detected 8 patients who had received 
RotaTeq® and were shedding the G1P[5]-vaccine strain. All these patients had 
simultaneously other gastroenteritis viruses in their stools. Four of these patients 
shed the vaccine virus identical to the G1P[5]-strain. In the other cases, the VP4 
was either negative in RT-PCR or two VP4 strains were detected by sequencing. 
The detection of two VP4s would indicate the presence of more than one vaccine 
virus, most likely G1P[5] and G6P[8] reassortants separately. 
 
 
LABORATORY FINDINGS 
 
In patients 1 through 3, only one rotavirus was identified in the stool specimens 
by RT-PCR. In each case, the virus was a bovine rotavirus as determined by 
VP6 sequencing. Genotyping by RT-PCR confirmed that in each case the G-type 
was G1 and P-type was P[8].  
In all three specimens, analysis of nucleotide sequences revealed that a 860-
base pair (bp) fragment of the VP7 gene and a 570 bp fragment of the VP4 gene 
were 100% identical to cognate gene segments from the corresponding G1P[5] 
and G6P[8] viruses in RotaTeq®. Also, in all specimens, a 362bp fragment of 
VP6 gene segment was 100% identical to the WC3 cognate gene of RotaTeq®. 
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Neither RT-PCR nor sequencing detected any other rotavirus types in the stool 
specimens of these three patients.  
The stool specimen from Patient 3 was ELISA positive, with an optical density 
(OD) of 0.910 (Rotaclone-positive OD>0.15). For Patients 1 and 2 ELISA tests 
were negative. The ELISA positive stool specimen from Patient 3 could be 
propagated in MA104 cells. Upon five passages the virus remained stable as a 
double reassortant and the sequencing of VP7, VP4 and VP6 were identical to 
the original isolate.  
Other viral agents that were studied were norovirus, sapovirus, bocavirus and 
coronavirus. In the 3 cases, all tests for these viruses were negative.  
 
DISCUSSION 
 
We describe three patients with symptomatic gastroenteritis associated with 
vaccine-derived new G1P[8] human-bovine double reassortant rotavirus. This is 
a small number compared to the estimated 8000 infants that had received 
RotaTeq® vaccine in the 2 year period 2009-2011 in the coverage area of 
Tampere University Hospital. This was 3.8% of the 79 rotavirus positive cases of 
acute gastroenteritis detected during the two-year period. On the other hand, it is 
possible that the true rate of symptomatic gastroenteritis, and, probably, 
asymptomatic shedding, due to vaccine-derived double reassortant may be 
higher, since mild cases of gastroenteritis associated with vaccination, and much 
less asymptomatic shedding, would not be detected in a hospital based survey.  
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Wild-type rotavirus infects the mature enterocytes, and rotavirus may replicate for 
up to two weeks in the cells.14,15 For a double reassortant to develop, G1P[5] and 
G6P[8] reassortants would have to infect the same cell. Apparently this can 
happen in rare cases.7,8,16 It is of interest that all our cases as well as those 
reported previously are reassortants with G1 and not with other human G-types. 
G1 appears to be shed more commonly after vaccination than other G-types, 17 
and may therefore be more fit for multiplication. While the formation of a double 
reassortant between G1 and P[8] is more likely than other combinations it is not 
clear why a double reassortant G1P[8] should have greater virulence resulting in 
clinical symptoms. 
 
Two cases happened after the administration of the first dose of RotaTeq®. It is 
likely that multiplication of vaccine virus in the intestinal enterocytes is more 
effective after the first dose, possibly giving a greater chance of formation of new 
reassortants. Patient 2 had mild symptoms of gastroenteritis after the second 
dose. In this case it is possible that the first dose of RotaTeq® had not taken, 
perhaps due to presence of maternally acquired antibodies, and the second dose 
was effectively the first successful vaccination for this infant.18,19 
 
Our studies of viral culture showed that G1P[8] double reassortant appears 
stable in vitro. In the US, sibling transmission of vaccine-derived G1P[8] virus 
between an immunocompetent vaccinated sibling and a healthy 
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immunocompetent unvaccinated sibling has already been reported.8 It is not 
known, but plausible, that the double reassortant could remain in circulation even 
longer than one transmission cycle. As immunocompromised people may 
continue to shed the wild-type rotavirus and the vaccine-acquired rotavirus in 
their stools for several months, the prolonged replication increases the probability 
of adverse events and the possibility of infecting contacts.7  
 
Altogether, shedding of RotaTeq® vaccine virus in immunocompetent children 
appears to be more common than initially reported. In the REST study shedding 
was evaluated by viral culture with use of a plaque assay and RNA 
electropherotyping,1 which are relatively insensitive methods for detection of the 
vaccine virus.Other studies using ELISA, have revealed a shedding rate of 
21.4% (22/103) in full term infants and 53% (8/15)  in premature infants.20,21 
None of these studies detected any double reassortant viruses. 
 
Apart from the 3 cases with the double reassortant, we also saw one infant with 
symptomatic gastroenteritis shedding the original G6P[8] single reassortant 
vaccine virus. This raises the possibility that P[8] alone may be associated with 
symptoms and might also be the component resulting in increased virulence of 
the double reassortant. When RotaTeq® was being developed, a study was 
conducted to compare the pentavalent composition, quadrivalent (G1, G2, G3 
and G4) composition and monovalent (P1A[8]) composition.22 The results 
showed that the frequency of fever was higher after the first vaccination with 
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pentavalent vaccine than with the quadrivalent composition group, suggesting a 
role in virulence of P[8].  
 
Taken together, we propose that to induce diarrhea the VP4- protein from human 
origin has to be present in the vaccine virus, either as the new double reassortant 
G1P[8] or, perhaps, only as the original vaccine virus G6P[8]. 
 
 
CONCLUSION 
Formation of G1P[8] double reassortants may explain diarrheal symptoms in a 
small percentage of RotaTeq® recipients. The reassortment between two 
vaccine strains may occur during intestinal replication even in immunocompetent 
infants. Such a double reassortant virus appears stable and might also be 
transmitted to contacts in the environment. 
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